Therapy of small cell lung cancer with emphasis on oral topotecan

被引：12

作者：

Pirker, Robert ^{[1
]}

Berzinec, Peter ^{[2
]}

Brincat, Stephen ^{[3
]}

Kasan, Peter ^{[4
]}

Ostoros, Gyula ^{[5
]}

Pesek, Milos ^{[6
]}

Plate, Signe ^{[7
]}

Purkalne, Gunta ^{[8
]}

Rooneem, Regina ^{[9
]}

Skrickova, Jana ^{[10
]}

Stanculeanu, Dana ^{[11
]}

Timcheva, Constanta ^{[12
]}

Tzekova, Valentina ^{[13
]}

Zakotnik, Branko ^{[14
]}

Zielinski, Christoph C. ^{[1
]}

Zwitter, Matjaz ^{[15
]}

机构：

[1] Med Univ Vienna, Dept Med 1, A-1090 Vienna, Austria

[2] Specialised Hosp St Zoerardus Zobor, Dept Oncol, Nitra, Slovakia

[3] Sir Paul Boffa Hosp, Floriana, Malta

[4] Univ Hosp Bratislava, Dept Oncol, Bratislava, Slovakia

[5] Natl Koranyi Inst TB & Pulmonol, Budapest, Hungary

[6] Charles Univ Prague, Fac Med, Plzen, Czech Republic

[7] Riga Easten Univ Hosp, Riga, Latvia

[8] Paul Stradins Clin Univ Hosp Riga, Radiat & Chemotherapy Ctr, Riga, Latvia

[9] N Estonia Reg Hosp, Ctr Canc, Dept Chemotherapy, Tallinn, Estonia

[10] Univ Hosp, Dept Resp Dis & TB, Brno, Czech Republic

[11] Inst Oncol, Bucharest, Romania

[12] Specialized Hosp Active Treatment Oncol, Sofia, Bulgaria

[13] ISUL, Univ Hosp Queen Joanna, Clin Chemotherapy, Sofia, Bulgaria

[14] Inst Oncol Ljubljana, Div Med Oncol, Ljubljana, Slovenia

[15] Inst Oncol Ljubljana, Dept Radiat Oncol, Ljubljana, Slovenia

来源：

LUNG CANCER | 2010年 / 70卷 / 01期

关键词：

Chemotherapy; New drugs; Thoracic radiotherapy; Brain irradiation; Second-line therapy; Topotecan; PROPHYLACTIC CRANIAL IRRADIATION; PREVIOUSLY UNTREATED PATIENTS; CISPLATIN PLUS ETOPOSIDE; LONG-TERM SURVIVAL; PHASE-III TRIAL; PROGNOSTIC-FACTORS; THORACIC RADIOTHERAPY; 2ND-LINE TREATMENT; CHEMOTHERAPY; AMRUBICIN;

D O I：

10.1016/j.lungcan.2010.05.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Systemic chemotherapy plays the major role in the management of patients with small cell lung cancer. Cisplatin plus etoposide is the most widely used regimen and is considered as standard in patients with limited disease. Cisplatin plus irinotecan improved survival compared to cisplatin plus etoposide in a Japanese trial but failed to do so in two trials in Caucasians. Cisplatin plus topotecan had similar efficacy compared to cisplatin plus etoposide in patients with extensive disease. In the second-line setting, topotecan showed similar efficacy but better tolerability compared to cyclophosphamide, doxorubin plus vincristine. Oral topotecan was as efficacious as its intravenous formulation and was shown to improve survival compared to best supportive care alone in patients previously treated with chemotherapy. Thus topotecan is considered as the standard second-line chemotherapy in patients with small cell lung cancer. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

引用

页码：7 / 13

页数：7

共 50 条

[31] ACR Appropriateness Criterias® Radiation Therapy for Small-Cell Lung Cancer
Kong, Feng-Ming
Lally, Brian E.
Chang, Joe Yujiao
Chetty, Indrin J.
Decker, Roy H.
Ginsburg, Mark E.
Kestin, Larry L.
Langer, Corey J.
Movsas, Benjamin
Videtic, Gregory M. M.
Willers, Henning
Rosenzweig, Kenneth E.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2013, 36 (02): : 206 - 213
[32] Limited-Stage Small Cell Lung Cancer: How to Optimize Therapy?
Fournel, Pierre
ONKOLOGIE, 2012, 35 (06): : 332 - 333
[33] Phase II Study of Topotecan and Bevacizumab in Advanced, Refractory Non-Small-Cell Lung Cancer
Powell, Steven F.
Beitinjaneh, Amer
Tessema, Mathewos
Bliss, Robin L.
Kratzke, Robert A.
Leach, Joseph
Dudek, Arkadiusz Z.
CLINICAL LUNG CANCER, 2013, 14 (05) : 495 - 501
[34] Advances in Small Cell Lung Cancer
Kalemkerian, Gregory P.
Schneider, Bryan J.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (01) : 143 - +
[35] Emerging Strategies for the Treatment of Small Cell Lung Cancer A Review
Petty, W. Jeffrey
Paz-Ares, Luis
JAMA ONCOLOGY, 2023, 9 (03) : 419 - 429
[36] Combination therapy with carboplatin and paclitaxel for small cell lung cancer
Mouri, Atsuto
Yamaguchi, Ou
Miyauchi, Sachiko
Shiono, Ayako
Utsugi, Harue
Nishihara, Fuyumi
Murayama, Yoshitake
Kagamu, Hiroshi
Kobayashi, Kunihiko
RESPIRATORY INVESTIGATION, 2019, 57 (01) : 34 - 39
[37] Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer
Se Hoon Park
Eun Kyung Cho
Yujin Kim
Sun Young Kyung
Chang Hyeok An
Sang Pyo Lee
Jeong Woong Park
Sung Hwan Jeong
Jae-Ik Lee
Soo Jin Choi
Jinny Park
Dong Bok Shin
Jae Hoon Lee
Cancer Chemotherapy and Pharmacology, 2008, 62 : 1009 - 1014
[38] Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer
Park, Se Hoon
Cho, Eun Kyung
Kim, Yujin
Kyung, Sun Young
An, Chang Hyeok
Lee, Sang Pyo
Park, Jeong Woong
Jeong, Sung Hwan
Lee, Jae-Ik
Choi, Soo Jin
Park, Jinny
Shin, Dong Bok
Lee, Jae Hoon
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (06) : 1009 - 1014
[39] Progress in the therapy of small cell lung cancer
Simon, M
Argiris, A
Murren, JR
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2004, 49 (02) : 119 - 133
[40] Oral targeted therapy for non-small cell lung cancer
Phillips, William J.
Leighl, Natasha B.
Blais, Normand
Wheatley-Price, Paul
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2024, 196 (22) : E770 - E774

← 1 2 3 4 5 →